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A 9-year-old female spayed boxer was referred tothe Veterinary Teaching Hospital of the Univer-
sity of Bern for a history of chronic neck pain and
neurologic deﬁcits. One month before presentation, the
dog had been treated with carprofena (2 mg/kg once
daily) and ordered restriction of exercise. Clinical signs
improved transiently but, 1 week before presentation,
the dog relapsed despite continued treatment and man-
ifested severe cervical pain and gait problems, which
rapidly progressed to a nonambulatory status. Physical
examination was noncontributory. Neurologic exami-
nation revealed obtunded mentation along with a non-
ambulatory tetraparesis. Postural reactions were
decreased to absent in all four limbs, while segmental
spinal reﬂexes persisted intact. There were bilaterally
reduced menace responses and a spontaneous vertical
nystagmus. Passive lateral and dorsal ﬂexion of the
neck elicited a pain response. The neurologic status was
deemed to be consistent with a multifocal process in the
forebrain, brainstem, and cervical spinal cord (C1–C5),
possibly involving the meninges as well. At this stage,
diﬀerential diagnoses included both neoplastic and
inﬂammatory diseases with multifocal involvement. A
complete blood cell count, serum biochemistry proﬁle,
plasma ammonia concentration, fasting and postpran-
dial bile acids, T4 and TSH levels were all within refer-
ence ranges. Chest radiographs were unremarkable.
Magnetic resonance imaging (MRI) of the head
and neck was performed using a 1 Tesla Panorama
HFO from Philips under general anesthesia. Anesthe-
sia was induced with fentanylb (5 lg/kg IV) and
propofolc (4 mg/kg IV). This included T2-weighted
(T2W) sequences in sagittal and transverse planes,
ﬂuid-attenuated inversion recovery (FLAIR) sequences
in dorsal and transverse planes, dorsal and transverse
T1W pre- and postcontrast sequences, and transverse
T2*-weighted (T2W) gradient echo sequences. Scans
revealed a large left-sided, intra-axial space-occupying
lesion that was divided into two portions interconnected
by a thin isthmus at the level of the cerebellar tentorium
(Fig 1A,B). The mass was surrounded by extensive
perilesional edema (Fig 1A). The larger rostral portion
was located ventrolaterally in the cranial fossa, and
extended from the frontal to the piriform lobe; the smal-
ler portion was located laterally in the caudal fossa
above the petrous bone. The rostral portion of the mass
caused midline shift to the right, displacing and attenuat-
ing the ventral aspect of the left lateral ventricle. In
transverse sections, it was moderately delineated and
contained T2-hyperintense (Fig 1C), and T1-hypoin-
tense cavities that showed incomplete suppression on
FLAIR sequences. After contrast administration, the
ventral cavitary lesion appeared delineated by a con-
trast-enhancing rim (Fig 1D). An area with more hetero-
geneous contrast enhancement was located rostral to the
cavity (Fig 1B). The mass extended into the meninges at
the ventral margins of the piriform lobe and basal nuclei
(Fig 1C,D), where it showed strong and homogeneous
contrast enhancement (Fig 1D). No evidence of hemor-
rhage was found on T2* sequences. The caudal, subten-
torial portion of the mass was hypointense in T1W and
hyperintense in T2W images. In transverse sections, it
appeared to be predominantly extra-axial and shared
similar MRI characteristics with the rostral portion
(Fig 1E,F). Mild hydrocephalus and hydrosyringomy-
elia of the ﬁrst cervical segments of the spinal cord were
observed. Mild mucosal thickening with mild contrast
enhancement was observed in the left bulla. Further
diagnostic evaluation, including a stereotactic brain
biopsy, was declined by the owner. The dog was eutha-
nized at the owner’s request, and permission was granted
to perform necropsy (Figs 2, 3).
Gross examination of the brain revealed a round,
grayish, ill-deﬁned mass with soft to gelatinous consis-
tency in the left piriform and temporal lobe, causing
midline shift to the right. The mass abutted on the left
lateral ventricle, and extended to the meninges at the
base of the skull. The center of the mass was cystic.
The macroscopic appearance of the lesion in the cau-
dal fossa was similar. Histologic examination revealed
a biphasic tumor composed of alternating neuroepithe-
lial and mesenchymal cell populations. The former
displayed characteristics of conventional anaplastic
oligodendroglioma (WHO grade III). Dispersed on a
mucinous background, tumor cells exhibited roundish,
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nonﬁbrillary cytoplasmic contours, mildly irregular
hyperchromatic nuclei, and conspicuous perinuclear
vacuolation producing an overall honeycomb-like
texture. In between, several mucus-ﬁlled cysts were seen.
The tumor’s vasculature included both “chicken-wire”
type capillaries and complex festoons of glomeruloid
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Fig 1. (A) Dorsal FLAIR image at the level of the orbits, showing the large left-sided, intra-axial space-occupying lesion extending
from the cranial to the caudal fossa with extensive perilesional edema and incomplete suppression of the center of the cystic cavities. (B)
Dorsal T1-weighted image after gadolinium administration at the level of the orbits, showing the rostral and caudal portion of the lesion
connected by a thin isthmus at the height of the cerebellar tentorium. (C) Transverse T2W image and (D) transverse T1W image after
gadolinium administration showing rim-like contrast enhancement of the rostral portion of the lesion, and strong and homogeneous con-
trast enhancement of the meningeal inﬁltration at the ventral margins of the piriform lobe and basal nucleus. (E) Transverse T2W image
and (F) transverse T1W image after gadolinium administration of the subtentorial portion of the mass showing characteristics similar to
the rostral portion.
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Fig 2. (A) Frontal slice through the formalin ﬁxed the brain at necropsy showing an ill-deﬁned mass in the left piriform and temporal
lobe with multiple cystic cavities (asterisk). The mass has contact with the basal meninges (arrow). (B, C) Photomicrographs of the oli-
godendroglioma portion of the tumor, showing (B) a central cavity surrounded by a layer of neoplastic cells and microvascular prolifer-
ation (arrow) (H&E, 209) (scale bar = 5 mm); (C) classical honeycomb pattern of neoplastic cells encased by glomeruloid
microvascular structures (H&E, 2009) (scale bar = 50 lm); (D) (scale bar = 1000 lm). Photomicrographs of the sarcomatous portion
in the subarachnoid space showing (E) (scale bar = 50 lm) fascicles of spindle cells separated by broad bands of collagen (H&E, 1009
and 2009).
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proliferations. Up to 2 mitoses per 1 high-power ﬁeld
(HPF) were observed. Inﬁltrative growth was evident, as
were “secondary structures of Scherer” around vessels
and neurons. A pericellular basal lamina was not pres-
ent after staining with Gomori’s silver stain. Conversely,
the mesenchymal population was characterized by hap-
hazard fascicles of spindle cells on a mucinous matrix
and amidst an intricate mesh of Gomori-impregnated
pericellular basal lamina as well as broad bands of colla-
gen. Here up to 3 mitoses per 1 HPF were observed.
This portion of the tumor encroached upon the sub-
arachnoid space around the optic chiasm and pituitary
gland.
On immunohistochemistry, both tumor cell popula-
tions showed nuclear expression of Olig2.d Staining for
glial ﬁbrillary acidic protein (GFAP) (GFAP poly-
clonale ) tended to be restricted to interspersed reactive
astrocytes within the oligodendroglial component,
whereas some 5% of neoplastic spindle cells in the
sarcomatous areas were positive. In addition, neoplas-
tic cells in the sarcomatous but not the oligodendrog-
lial areas focally expressed vimentin (Vimentin clone
Vim3B4e), muscular actin (Muscle actin clone
HHF35e), and smooth muscle actin,f but not S100
(S100 polyclonal and Desmin clone D33e) protein.
Irrespective of architectural variations, the Ki-67
(MIB-1; Ki 67 clone MIB1e) labeling index averaged
5%. Based on the above ﬁndings, the tumor was diag-
nosed as anaplastic oligodendroglioma with heterolo-
gous sarcoma-like diﬀerentiation (“oligosarcoma”).
Discussion
Glial tumors are the second most common primary
intracranial neoplasm in dogs, and account for 35% of
neuroepithelial tumors.1 The two most common clinical
signs associated with primary intracranial tumors of
dogs located in the telencephalon are seizures and
altered mentation.1 In contrast, the dog described in
this report was presented initially with severe neck
pain. This might have been because of hydrosyring-
omyelia of the ﬁrst cervical segments, which has been
associated with persistent neuropathic pain in other
breeds.2,3
Based on histologic similarities to human CNS
tumors, the 2007 World Health Organization (WHO)
classiﬁcation system of human CNS tumors has been
tentatively applied to the taxonomy and grading of vari-
ous canine CNS tumors.4–8 With the exception of a con-
spicuous oligodendroglial—rather than astrocytic—
background, the microscopic and immunohistochemical
features of the tumor described were consistent with a
diagnosis of gliosarcoma, the latter being deﬁned as “a
glioblastoma variant characterized by a biphasic tissue
pattern with alternating areas displaying glial and mes-
enchymal diﬀerentiation”.9 The glial moiety of gliosar-
comas per deﬁnitionem involves astrocytic
diﬀerentiation.4–10 Alternatively, the descriptive labels
“oligosarcoma” and “ependymosarcoma” have been
proposed to accommodate those hybrid neuroepithelial-
sarcomatous malignancies—exceedingly rare as a group
—wherein the glioma component exhibits either oligo-
dendrocytic or ependymal phenotype, respectively.9,11–
13 In our case, the anaplastic oligodendroglial element
(WHO grade III) was diagnosed based on the presence
of a monomorphous population of round cells with hy-
perchromatic nuclei strongly staining with Olig-2, hon-
eycomb texture, microvascular proliferation, and brisk
mitotic activity.4 On the other hand, criteria for classify-
ing the mesenchymal population as an undiﬀerentiated
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Fig 3. (A) Neoplastic cells of the conventional oligodendroglioma portion lack a pericellular basal membrane (Gomori’s silver stain,
4009) (scale bar = 50 lm). (B) Neoplastic cells of the sarcomatous portion are surrounded by a pericellular basal membrane (Gomori’s
silver stain, 4009) (scale bar = 50 lm). (C, D) Nuclear anti-Olig2 positivity in neoplastic cells of both the oligodendroglial (C) and sar-
comatous (D) portion (anti-Olig2 immunohistochemistry, 2009) (scale bar = 100 lm). (E, F) Immunohistochemistry for vimentin. In the
oligodendroglial portion (E), vimentin is only expressed by microvascular structures, whereas neoplastic oligodendrocytes lack expression
(1009); in the sarcomatous portion, neoplastic cells multifocally expressed vimentin (F, 1009). (G, H) Immunohistochemistry for
smooth muscle actin (SMA). Similar to vimentin, in the oligodendroglial portion SMA is expressed by microvascular proliferations and
intraneoplastic vessels only (G), whereas in the sarcomatous portion (H), SMA is multifocally expressed by neoplastic cells (1259) (scale
bar = 100 lm). [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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“sarcoma” included cytologically anaplastic spindle cells
surrounded by pericellular basal lamina, high mitotic
activity, and briskly elevated MIB-1 labeling index.
Although we did not feel this component ﬁt into any of
the individualized sarcoma entities acknowledged by the
current WHO classiﬁcation of soft tissue and bone
tumors, expression of desmin and smooth muscle
actin nevertheless indicated smooth muscular–related
lineage.14
Although oligodendroglioma is common in dogs,1,7,9
oligosarcoma has not been previously reported. In
humans, diﬀerentiation of oligosarcoma from
gliosarcoma has been suggested to directly impact on
clinical decision making, because oligodendroglial dif-
ferentiation tends to confer signiﬁcant advantage with
respect to both prognosis and adjuvant treatment
options.9–12,15–17 Clinical prospective studies would be
necessary to evaluate any possible impact of oligoden-
droglial diﬀerentiation on the biologic behavior of
biphasic glial tumors in dogs. Reports on human oli-
gosarcomas9–11,15,16 suggest that these tumors result
from sarcomatous transformation of oligodendroglio-
mas, as they tend to occur in patients with a long his-
tory of clinical signs or upon tumor recurrence after
surgical, medical, or radiation treatment. In contrast,
the dog described in this report had a relatively short
history and no history of treatment other than anti-
inﬂammatory drugs.
Oligodendrogliomas typically present as single, fairly
well-delineated, round, intra-axial masses arising in the
cerebral hemispheres, sometimes extending to the sub-
arachnoid space on MRI examination.5–8 In the dog
presented here, the intra-axial portion of the mass,
which was predominated by the oligodendroglial popu-
lation, exhibited features of a conventional anaplastic
oligodendroglioma2 including hypointensity in T1W
sequences, hyperintensity in T2W sequences, presence
of ﬂuid-ﬁlled cavities with incomplete suppression in
FLAIR images (interpreted as focal areas of necrosis
or proteinaceous ﬂuid accumulation), along with ring-
like contrast enhancement. In contrast, a signiﬁcant
portion of the oligosarcoma moiety obliterated the
subarachnoid space, extending from the temporal lobe
into the caudal fossa. Here, the sarcomatous elements
prevailed, and showed strong and homogeneous con-
trast enhancement. It is conceivable that these diﬀerent
MRI patterns within the oligosarcoma are related to
the coexistence of both oligodendroglial and sarcoma-
tous components.
In conclusion, oligosarcoma—although rare—should
be considered in the diﬀerential diagnosis of canine
CNS tumors. As MRI cannot be used to reliably dif-
ferentiate oligosarcoma from other glial tumors, brain
biopsy is essential for deﬁnitive diagnosis. The occur-
rence of oligosarcoma in dogs adds a novel facet to the
histologic versatility of canine oligodendroglial tumors
and emphasizes their phenotypical similarity to their
human counterparts. Whether the analogy goes beyond
a shared morphologic repertoire, eg, commonalities in
molecular signatures, clinical behavior, and responsive-
ness to treatment, merits further investigation. Such
insight will have the potential to directly beneﬁt veteri-
nary patients.
Footnotes
a Panorama 1.0T HFO; Philips Healthcare, DA Best, The Neth-
erlands
b Propofol Fresenius 1%; Fresenius Kabi, Oberdorf, Switzerland
c Fentanyl–Curamed; Actavis, Regensdorf, Switzerland
d Anti Olig2, (AB9610) polyclonal; Millipore, Billerica, MA
e Dako, Glostrup, Denmark
f Smooth muscle actin clone 1A4; Sigma, St Louis, MO
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